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Objective: Age 65 years and older is generally considered a contraindication to lung
transplantation. Our group has offered lung transplantation to select patients 65 years
of age and older who lack other comorbid conditions. We sought to define the short-
and medium-term outcome of lung transplantation in patients aged 65 years and older.
Methods:We reviewed the records of our lung transplant recipients fromMarch 2000
to September 2006. During this interval, 50 patients were 65 years or older at the time
of transplantation. Fifty patients younger than 65 years were matched to the older
cohort by means of propensity analysis. The demographics and perioperative and
postoperative characteristics and survival of the 2 groups were compared.
Results: Older patients were more likely to receive single-lung transplantation (older
group: 76% vs younger group: 16%, P , .05) and nonstandard donor lungs (older
group: 46% vs younger group: 28%, P 5 .06). The composite in-hospital morbidity
rate was similar in the older and younger groups. There was no significant difference
in the early oxygenation parameters, incidence of acute cellular rejection, or incidence
of bronchiolitis obliterans syndrome between the 2 groups. The early survival of the
older patients was 95.7% compared with 95.9% in the younger cohort (P5 .73). The
1-year survival of the 2 groups was also similar (older group: 79.7% vs younger
group: 91.2%, P 5 .16). The 3-year survival of the older and younger recipients
was 73.6% and 74.2%, respectively (P5 .64). There were 8 deaths in the older recip-
ient group during the 1-month to 1-year posttransplantation interval, predominantly
because of infections.
Conclusions: Lung transplantation can be performed in patients older than 65 years
with acceptable clinical outcomes. The ‘‘increased’’ mortality of older patients
between 1 month and 1 year after transplantation, predominantly from infectious
causes, might be due to immunosenescence of older patients. This finding warrants
adjustments in the immunosuppression protocol of older patients undergoing lung
transplantation. The effect of offering lung transplantation to older patients on donor
lung availability deserves further investigation.
W
ithholding life-saving therapies from a certain cohort of patients because of
their advanced age is not considered acceptable in the Western world. Yet
in the field of organ transplantation, it is common practice to exclude older
recipients. The rationale for such practice includes limited donor supply and lower
survival of older patients after transplantation. In fact, the consensus guidelines for
selection of lung transplant recipients recommends an upper age limit of 65 years
for single-lung transplantation and 60 years for double-lung transplantation.1 Ad-
vanced recipient age has also emerged as an independent predictor of death after
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ATG 5 anti-thymocyte globulin
BOS 5 bronchiolitis obliterans syndrome
CMV 5 cytomegalovirus
CPB 5 cardiopulmonary bypass
FIO2 5 fraction of inspired oxygen
IPF 5 interstitial pulmonary fibrosis
ISHLT 5 International Society for Heart and Lung
Transplantation
LAS 5 Lung Allocation Score
PaO2 5 partial pressure of oxygen in arterial blood
UCLA 5 University of California Los Angeles
UNOS 5 United Network for Organ Sharing
lung transplantation in the International Society for Heart and
Lung Transplantation (ISHLT) registry.2
Despite these strong arguments, several reports in the past
decade have demonstrated that older recipients can undergo
kidney, liver, and heart transplantation and be treated with
immunosuppressive therapy with acceptable outcomes.3-6
In 1993, Snell and colleagues7 reviewed their lung transplan-
tation experience in elderly patients; the survival of 5 patients
older than 60 years was similar to that of the younger cohort.
More recently, Smith and associates8 reported their lung
transplantation experience with 16 patients older than 65
years. The survival of this cohort was similar to that of a con-
temporaneous younger group. Although advanced age re-
mains a contraindication in many transplantation centers,
a survey of active US lung transplantation programs showed
that 24% of programs do not consider age of greater than 60
years a contraindication to bilateral lung transplantation. In
the case of single-lung transplantation, approximately 20%
of active programs did not consider age of 65 years or older
to be an absolute contraindication.9
Starting in 1999, we have not used advanced age as an ab-
solute contraindication in the selection of lung transplant re-
cipients. We have offered lung transplantation to select older
patients (.65 years) who lack other comorbid conditions.
The purpose of this report is to compare the outcome of
lung transplantation in older recipients with that in a matched
younger cohort. The primary end points were 30-day, 1-year,
and 3-year survival. The secondary end points included early
oxygenation parameters, composite in-hospital morbidity
rates, and the incidence of acute rejection and bronchiolitis
obliterans syndrome (BOS).
Materials and Methods
Study Design
This study was reviewed and approved by the University of Califor-
nia Los Angeles (UCLA) Institutional Review Board. We retrospec-
tively analyzed the records of all patients who underwent lung
transplantation at the UCLA Medical Center from March 1, 2000,The Journal of Thothrough September 30, 2006. During this interval, 50 transplanta-
tions were performed on 48 patients 65 years of age or older (range,
65–72 years; older group) at the time of transplantation. For compar-
ison purposes, we matched each older patient with a recipient youn-
ger than 65 years (younger group) by means of propensity score
analysis using the criteria of diagnosis, date of transplantation,
and Lung Allocation Score (LAS).10 LASwas available for all trans-
plant recipients after the institution of the new allocation system in
May 2005. For patients undergoing transplantation before May
2005, LAS was tabulated after chart review by using the United
Network for Organ Sharing (UNOS) Web site LAS calculator
(http://www.unos.org/resources/frm_LAS-Calculator). If diagnos-
tic tests had been performed more than 6 months before transplan-
tation, they were used as up-to-date information for the LAS
calculation.
Donor and recipient characteristics, operative variables, and
posttransplantation characteristics were compiled for both the older
recipients and their matched younger cohorts.
Recipient Selection Criteria
Lung transplant recipients younger than 65 years were selected ac-
cording to the ‘‘International guidelines for the selection of lung
transplant candidates.’’1 Since 1999, we have offered lung trans-
plantation to a select a group of patients aged 65 years and older.
Relative contraindications for listing patients aged 65 years and
older were body mass index of less than 18 or greater than 30, pres-
ence of obstructive coronary artery disease, presence of peripheral
or cerebrovascular disease, renal insufficiency (creatinine clearance,
,50 mL/min), and debilitation. All recipients were informed of the
nonstandard donor lung program and consented.
Clinical Management Protocol
Single-lung transplantation was performed according to the standard
techniques.11 Cardiopulmonary bypass (CPB) was used only as
dictated by the recipient’s hemodynamics. All double-lung trans-
plantations were performed during CPB. All patients (single- and
double-lung transplant recipients) except one received modified
reperfusion after transplantation. The details of this technique
have been previously reported.12
All lung transplant recipients received induction immunosup-
pressive therapy. In older patients we used basiliximab (Novartis,
East Hanover, NJ), whereas in the younger cohort we favored rabbit
anti-thymocyte globulin (ATG) as the induction agent (Genzyme,
Cambridge, Mass). The induction therapy was followed with tacro-
limus, mycophenolate mofetil, and a steroid regimen. All patients
underwent surveillance biopsies at weeks 1, 4, 8, 12, and 24 and
as clinically indicated. All recipients were treated with broad antimi-
crobial therapy during the first posttransplantation week. Oral tri-
methoprim–sulfamethoxazole was administered biweekly for
prophylaxis against Pneumocystis carinii infections. Cytomegalovi-
rus (CMV)–positive recipients received intravenous ganciclovir
(Roche, Nutley, NJ) during hospitalization and were transitioned
to valganciclovir (Roche, Nutley, NJ) for the first year or longer if
inflicted with CMV infection. CMV-negative recipients who re-
ceived a CMV-positive donor were also treated with CytoGam
(CSL Behring, King of Prussia, Pa). The latter group also received
acyclovir (GlaxoSmithKline, Bridgewater, NJ) for herpes simplex
viral prophylaxis. Pulmonary function tests were performed at least
once every 3 months and at each clinic visit.racic and Cardiovascular Surgery c Volume 135, Number 2 413
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Recipient diagnoses were divided into 3 categories: obstructive pul-
monary disease, restrictive pulmonary disease, and other. Obstruc-
tive pulmonary diseases included emphysema and a1-antitrypsin
deficiency. Restrictive lung diseases included interstitial pulmonary
fibrosis (IPF), usual interstitial pneumonia, nonspecific interstitial
pneumonia, allergic alveolitis, scleroderma, rheumatoid arthritis, pol-
ymyositis, and sarcoidosis. Other end-stage lung diseases included
bronchiectasis, cystic fibrosis, IgA deficiency, lymphangioleiomyo-
matosis, primary pulmonary hypertension, and granulomatous lung
disease.
Nonstandard donor lungs were defined as follows: presence of
lobar infiltrate on chest roentgenographic analysis (atelectasis was
ruled out by means of preoperative and intraoperative treatment/
assessment), hypoxemia (partial pressure of oxygen in arterial blood
[PaO2] of ,300 on a fraction of inspired oxygen [FIO2] of 1.0 and
a peak end-expiratory pressure of 5), age of donor greater than
55 years, and a smoking history of greater than 20 pack-years.13
Allograft ischemic time was defined as the time of donor aorta
crossclamping to the time of lung reperfusion. In double-lung
transplantation the reperfusion of both lungs was done after implan-
tation of the second lung.
Blood gases were assessed at 6, 24, 48, and 72 hours after arrival
in the intensive care unit. The PaO2/FIO2 oxygenation parameters
were collected on all recipients. The worst blood gas value within
6 hours of the specified time point was used to determine the
PaO2/FIO2 ratio. The in-hospital complications that were collected
include atrial fibrillation requiring antiarrhythmic therapy, wound
complication requiring surgical intervention, renal failure requiring
dialysis, pulmonary embolus, gastrointestinal bleeding requiring
diagnostic endoscopy, and cerebrovascular accident (transient or
permanent neurologic deficit and consistent radiographic findings).
To allow comparison, a composite in-hospital morbidity index was
calculated for each group.
Acute cellular rejection was diagnosed by means of transbron-
chial lung biopsy and graded according to the ISHLT guidelines:
grade 0 (no rejection), grade A1 (minimal), grade A2 (mild), grade
A3 (moderate), and grade A4 (severe).14 BOS was assessed on
a 5-stage scale, as defined by a modification of the ISHLT consensus
statement.15 We defined the baseline as an average of the 2 best spi-
rometric values obtained in the first 6 months after transplantation. If
significant decreases in spirometric function were noted, then the
patient’s clinical record was evaluated to ensure no confounding
factors, such as infection, acute rejection, airway complications, or
underlying disease recurrence, were apparent. Biopsies for diagno-
sis of BOS were not routinely performed.
We had complete follow-up on all patients in this study. Cause of
death was obtained either from the death note in the medical record
or by means of autopsy report.
Statistical Analysis
Actuarial survival rates and freedom from BOS rates were plotted as
Kaplan–Meier estimates and compared by using Cox regression
models with robust variance estimators accounting for matched
patient pairs. The c2 or Fisher exact tests were used, as appropriate,
to test whether associations existed between groups for categorical
variables. Continuous characteristics were compared by using the Stu-
dent t test. TheWilcoxon rank sum test was used to compare medians414 The Journal of Thoracic and Cardiovascular Surgery c Febrbetween groups. The data were presented as means and SDs of the
mean, unless indicated otherwise. All analyses were performed with
Stata software (version 9.0; StataCorp, College Station, Tex).
Results
From March 2000 through September 2006, 214 patients
underwent 217 lung transplantations at UCLA. Fifty (23%)
of 217 of lung transplantations were performed in patients
aged 65 years and older. The number and percentage of trans-
plantations performed in patients older than 65 years in-
creased over this study period (Figure 1). Before 2003, 7
(14%) of 50 of the total transplantations were performed in
patients 65 years and older. Since 2003, 43 (25.7%) of 167
transplantations were performed in older patients.
Donor Information
The donor characteristics for recipients in the older group and
theirmatched cohorts are presented in Table 1. Themedian do-
nor age, donor sex, cause of death, and donor oxygenation pa-
rameters were similar when the older recipient group and the
younger matched cohort were compared. Forty-six percent
of donor lungs for the older recipients were classified as
nonstandard lungs compared with 28% of donor lungs in the
younger group (P5 .06). Older donors were preferentially al-
located to the older recipients. Sixty-one percent of older recip-
ients of nonstandard lungs received lungs from donors older
than 55years comparedwith 29%of theirmatchedyounger co-
horts. This difference reached statistical significance (P, .05).
Recipient and Perioperative Characteristics
The recipient demographics and perioperative characteristics
are presented in Tables 2 and 3, respectively. As expected,
there was a difference in the median age of the 2 groups.
The oldest patient to undergo lung transplantation during
this period was 72 years old. There was no statistical differ-
ence in recipient sex, incidence of diabetes mellitus, preoper-
ative mean pulmonary artery pressure, and waiting time
between the 2 groups. As expected, the diagnoses and
LASs were similar in both groups because the control youn-
ger recipients were matched to the older recipients based on
Figure 1. Lung transplantations performed at the UCLA Medical
Center (2000–2006).uary 2008
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both groups was less than 3 months. Analysis of our data be-
fore and after implementation of the new allocation system in
May 2005 revealed that the median waiting time for our
transplantation population has decreased: before May 2005,
the median waiting time was 107 days, whereas after May
2005, the median waiting time was 47 days (P , .05).
Older recipients were preferentially treated with single-
lung transplantation (Table 3). Seventy-six percent of older
recipients received single-lung transplants compared with
TABLE 1. Clinical characteristics of lung transplant donors
for the older and younger recipient groups
Older Younger
Median donor age (%) 36 (11–74) 36 (14–68)
Sex (% male) 58 66
Cause of death
Atraumatic brain injury 42 44
Traumatic head injury 34 46
Other traumatic injuries 4 2
Other 20 8
PaO2/FIO2 (mm Hg)
Best 386 6 91 405 6 85
Worst 352 6 93 345 6 66
Nonstandard donor lungs (%) 46 28
Reason for nonstandard lungs*
Radiographic infiltrate 17 14
Donor Age .55 yy 61 29
PaO2/FIO2 ,300 39 43
Presence of purulent secretions 30 36
Smoking history .20 pack-yearsy 4 36
One pack-year is defined as 1 pack of cigarettes smoked per day for 1 year.
PaO2, Partial pressure of oxygen in arterial blood; FIO2, fraction of inspired
oxygen. *Subclassification of the reason for nonstandard lung transplants
is reported as a percentage of the number of total nonstandard lungs in
each cohort. The total percentages exceed 100% because many donor
lungs had several nonstandard criteria. yP , .05 when older and younger
groups were compared.
TABLE 2. Demographics of older lung transplant recipients
and their matched younger cohort
Older Younger
Median age (y)* 66 (65–72) 58 (33–64)
Sex (% male) 60 54
Diagnosis (%)
Restrictive disease 58 58
Obstructive disease 36 36
Other 6 6
LAS score 39.9 6 7.8 38.9 6 7.2
DM (%) 16 8
Preoperative MPAP (mm Hg) 25.2 6 8.8 27.4 6 9.3
Waitlist time (d) 63 (3–298) 78 (1–703)
LAS, Lung Allocation Score; DM, diabetes mellitus;MPAP, mean pulmonary
artery pressure. *P , .05 when older and younger groups were compared.The Journal of Tho16% of younger recipients (P, .05). The rationale for offer-
ing double-lung transplantation to the remaining 24% of the
older recipients included severe pulmonary hypertension or
infectious lung diseases. As expected, more lung transplanta-
tions in younger patients were performed during CPB
(because the greater percentage received double-lung
transplants). The duration of CPB (for those recipients whose
procedures were performed during CPB), the allograft ische-
mic time, and the percentage of patients requiring concomi-
tant cardiac procedures were similar in both groups.
There were no intraoperative deaths. The median dura-
tions of mechanical ventilation, intensive care unit stay,
and hospital stay were also similar between the older group
and the matched younger cohorts. As noted in the Materials
andMethods section, the 2 groups were treated with different
induction therapy protocols; the older recipients are treated
with the anti–interleukin 2 receptor antibody, whereas most
of the younger recipients received rabbit ATG.
The oxygenation parameters at 24, 48, and 72 hours were
similar in the older versus younger recipient groups (Fig-
ure 2). Notably, the composite in-hospital morbidity rate
was also similar in both groups (Table 3); the older recipients
TABLE 3. Perioperative characteristics of older lung
transplant recipients and their matched younger cohort
Older Younger
Double-lung transplantations (%)* 24 84
CPB
Done on CPB (%)* 34 84
CPB time (min) 183 6 50 214 6 69
Allograft ischemic time (min)
Single-lung transplantations 263 6 50 295 6 59
Double-lung transplantations 346 6 88 367 6 60
Concomitant cardiac procedures (%) 16 26
Reoperation (%) 4 4
Median ventilator time (h) 27 (11–435) 30 (13–159)
Median intensive care unit stay (d) 4 (2–182) 6 (2–56)
Median hospital stay (d) 14 (8–277) 14 (7–98)
Induction therapy (%)
Rabbit ATG* 33 76
IL-2R antibody* 67 24
Composite in-hospital morbidity rate (%) 34 30
Atrial fibrillation 22 28
Wound complication 4 2
ARF requiring dialysis 6 8
Pulmonary embolus 0 4
GI bleed 6 2
CVA 0 0
Acute cellular rejection (episodes/
patient-y)
0.22 0.16
Grade A3 and greater acute cellular rejection was defined as episodes per
patient-year. CPB, Cardiopulmonary bypass; ATG, anti-thymocyte globulin;
IL-2R, interleukin 2 receptor; ARF, acute renal failure; GI, gastrointestinal;
CVA, cerebrovascular accident. *P , .05 when older and younger groups
were compared.racic and Cardiovascular Surgery c Volume 135, Number 2 415
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dence of acute rejection (grade A3 or higher) during the study
period was also similar in both groups (Table 3).
The presence of BOS was defined as a 20% or greater
decrease in the forced expiratory volume in 1 second from
baseline value. Nearly one third of older recipients were
given diagnoses of BOS by the end of the first posttransplan-
tation year compared with 16.1% of the younger cohort (Fig-
ure 3). After 12 months, the prevalence of BOS in the older
cohort reached a plateau, whereas it increased in the younger
cohort. Overall, there was no statistically significant differ-
ence in the prevalence of BOS between patients older than
65 years versus those younger than 65 years. Furthermore,
we could not detect a difference in survival from the time
of diagnosis of BOS in older patients who received single-
Figure 2. Postoperative partial pressure of oxygen in arterial
blood (PaO2)/fraction of inspired oxygen (FIO2) ratio in lung trans-
plant recipients aged 65 years and older and their matched youn-
ger cohort.
Figure 3. Freedom from bronchiolitis obliterans syndrome (BOS)
after lung transplantation in the older and younger recipient
groups. Patients were considered to have BOS if there was
a greater than 20% decrease from baseline forced expiratory vol-
ume in 1 second values (ie, stage I or greater BOS on the basis of
ISHLT criteria).416 The Journal of Thoracic and Cardiovascular Surgery c Feblung transplants versus the younger patients who received
double-lung transplants (likely because of a small number
of index cases in both groups).
The median follow-up period for the older and younger
groups was 15 and 19 months, respectively (P 5 .54). The
early (in-hospital, 30 days, or both) survival in the older group
was 95.7%, and it was 95.9% in the younger matched cohort
(P5 .73, Figure 4). The 1-year survival in the older groupwas
79.7%, with 8 deaths during the 1-month to 1-year posttrans-
plantation interval. The 1-year survival in the control cohort
(,65 years) was 91.2%, with 3 deaths during the 1-month
to 1-year posttransplantation period. There was not a statisti-
cally significant difference in the 1-year survival of the 2
groups (P 5 .16). The causes of death in the older group in-
cluded infections (n 5 6), cardiovascular issues (n 5 1),
and BOS (n5 1, Table 4). The 3 deaths in the younger group
during this interval were due to infections (n 5 2) and un-
known causes (n 5 1). None of the deaths in the single-lung
transplant recipients could be attributed to the remaining na-
tive lung. The survival curve of the older group reached a pla-
teau at 18months and has been stable up to 3 years. The 3-year
survival of the older recipients was 73.6%, whereas that of the
younger matched group was 74.2% (P5 .64).
Figure 4. Kaplan–Meier survival curves for lung transplant recip-
ients aged 65 years of age and older and their matched younger co-
hort. There was no significant difference between the 2 survival
curves.
TABLE 4. Causes of death from 30 days to 1 year after
transplantation in the older and younger recipient groups
Older Younger
Causes of death (30 d–1 y)
Infection 6 2
BOS 1 0
Cardiovascular 1 0
Unknown 0 1
Total 8 3
Six of 8 deaths in the older group were attributed to infectious causes.ruary 2008
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This study demonstrates that lung transplantation can be per-
formed in select patients older than 65 years with acceptable
short- and medium-term survival. The morbidities associated
with this procedure (composite in-hospital morbidities, inci-
dence of acute cellular rejection, and BOS) were also similar
between the older and younger groups.
These observations are predicated on several program-
matic guidelines that deserve special emphasis. First, the
older recipients were selected by using strict previously noted
criteria. We ensured that older recipients were otherwise
healthy candidates, with at most 1 relative contraindication.
Second, we favor single-lung transplantation in older
recipients. Older recipients have been known to have better
outcomes with single-lung transplantation compared with
double-lung transplantation.16,17
Third, the immunosuppression regimen was tailored in
older recipients. The findings of this study need to be ana-
lyzed within the context of the above caveats. The similarity
of clinical outcomes in the older versus younger recipients in
our experience might be due to our clinical management
protocols (donor and recipient selection and management),
small sample size in this study, or both.
Nonstandard donor lungs were preferentially allocated to
older recipients. Use of nonstandard donor lungs is associ-
ated with higher perioperative mortality.18 The similar early
outcome of the older and younger groups, despite this alloca-
tion bias, might be due to (1) the small number of patients in
both groups (type II error) or (2) bias in the selection of
‘‘quality’’ nonstandard donor lungs when needed for sin-
gle-lung transplantations in older recipients, or (3) higher
perioperative mortality of double-lung transplantation17 in
the younger group might balance the early perioperative mor-
tality in the older group because of nonstandard donor lung
dysfunction.
Despite the similarities of the early- and medium-term sur-
vival of the older group and the matched younger cohort,
there were 8 deaths in the older group in the 1-month to
1-year period after lung transplantation. The majority of these
deaths were attributed to infectious causes. Although our im-
munosuppression regimen was tailored in the older recipient
group (interleukin 2 receptor blockade instead of rabbit ATG
for induction therapy), it remains a possibility that overim-
munosuppression in the older recipients might have contrib-
uted to life-threatening infections. Immunosenescence is
a well-recognized entity in older individuals.19,20 Potential
mechanisms of age-based differences in posttransplantation
immune response include replicative senescence, thymic in-
volution, degeneration of the T-cell repertoire, alterations in
T-suppressor activity, altered cytokine profiles, and reduced
perforin production.21,22 Moreover, several studies have
shown that the incidence of acute cellular rejection in elderly
recipients of kidney, liver, heart, and lung transplants are
lower compared with that seen in younger recipients.4-7 InThe Journal of Thothis study the incidence of acute cellular rejection was similar
in the elderly group and the matched younger cohort.
Based on the findings of this study, it is reasonable to alter/
reduce the immunosuppression regimen in older lung trans-
plant recipients. A reduction in the dose of calcineurin inhib-
itors can lead to a reduction in the renal side effects;
adjustments in the dose of steroids can also decrease the asso-
ciated metabolic complications. The potential benefits of
such adjustments, provided that the incidence of acute rejec-
tion and BOS do not increase, are significant. A more robust
recipient immune system can combat infections more
vigorously.
This study does not support widespread application of
lung transplantation to older recipients. In fact, larger data-
bases, such as UNOS/ISHLT registry, might be the only rea-
sonable basis on which to change the current guidelines. In
a recent report 42 older lung transplant recipients were
matched to a younger cohort, and their survival was com-
pared. The medium-term and long-term survival of the older
recipients was significantly lower, even after adjustment for
the older group’s expected higher age-related mortality.23
Another important issue in offering lung transplantation to
older recipients is the effect on donor supply. Given the lim-
ited donor pool, expanding the recipient pool by offering
lung transplantation to older recipients will ultimately de-
prive a younger recipient of a potential donor organ. One
might address this ethical dilemma by (1) informing all older
recipients about a nonstandard donor pool program preoper-
atively and (2) preferential offering of nonstandard donor
lungs to older recipients. Despite the adoption of these poli-
cies, more than half of our older recipients received donor
lungs from the standard pool. A consensus on the definition
of the nonstandard donor and recipients and UNOS adoption
of a policy of allocating nonstandard donor organs to non-
standard recipients might be a solution to this ethical di-
lemma. Until then, the effect of lung transplantation in
older recipients on the donor pool and other younger patients
on the waiting list is an important question and deserves
further study.
This study has several limitations. First, this is a retrospec-
tive case-control analysis with all the inherent limitations of
such a study.
Second, the index older cases were matched to the youn-
ger recipients based on their diagnoses, severity of disease
(by using LAS as surrogate marker), and the era of transplan-
tation. Another factor that is known to affect short-term
outcome after lung transplantation is the type of transplanta-
tion.16,17 We did not match for the type of transplantation
(single vs double) because there were insufficient double-
lung transplant recipients in the older group and single-
lung transplant recipients in the younger group. The findings
of this study might not be applicable when comparing the
outcome of the type of transplantation in older versus youn-
ger recipients.racic and Cardiovascular Surgery c Volume 135, Number 2 417
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small number of cases in both groups, thus requiring larger
differences in clinical outcomes to detect statistically signif-
icant differences (type II error).
Fourth, although strict criteria were used in the selection
of both the older and younger recipients, the final approval
for lung transplantation was dependant on the decision of
the multidisciplinary lung transplant selection committee.
There might be inherent bias against selection of older
patients based on overall clinical fitness and extent of
comorbidities.
Fifth, another limitation of this study is the short follow-up
time. Longer follow-up analyses are needed to assess the
safety and clinical outcome of lung transplantation in older
recipients.
Finally, this study only compares the survival of older and
younger lung transplant recipients. Lung transplantation
might not only affect survival but also the quality of life.
We have no objective information on the quality of life after
lung transplantation in the older or younger recipients as part
of this study. The real effect of lung transplantation can only
be assessed when survival and quality-of-life data are ana-
lyzed together.
In summary, lung transplantation can be performed safely
andwith comparable short-term andmedium-term survival in
selected patients older than 65 years.
Posttransplantation-related infections represent the major
cause of early mortality that might require adjustments in
immunosuppression protocols. Multidisciplinary consensus
is needed to determine the ethical standards in offering
lung transplantation to the elderly given the critically short
supply of donor organs.
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Discussion
Dr John C.Wain (Boston, Mass). I appreciate the chance to discuss
the article. Certainly I think the results are quite good, and Drs Bas-
tani and Ardehali and their colleagues are to be congratulated on
having not only completed this study but also their superlative re-
sults in terms of operative and perioperative morbidity and mortality
looking in a retrospective fashion at patients older than 65 years of
age. I think it is important to recognize that age greater than 65 years
is actually a pretty narrow window; it is just 65 to 72 years of age as
the maximum. Therefore we still have a question out there about
even older patients. That being said, though, the results still stand
for themselves in terms of the operative and perioperative morbidity
and mortality.
Before I get to specific questions, I would like to say that the
study also seems to validate 2 other things that are emerging con-
cepts, if you will, at least about lung transplantation in the United
States. The first is that the LAS system works. As I think you found
in your manuscript, the time waiting at a busy transplantation center
was reduced from 107 days to 47 days. Therefore the LAS is clearly
an improvement.ruary 2008
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modern era of lung transplantation, and I think that that is an inter-
esting observation, certainly one that seems to be growing and that
probably relates to standardized procurement and preservation and
the techniques of implantation.
But to return to the main thrust of the article, there were 3 con-
clusions I think they tried to stress. One is that lung transplantation
in older patients is safe, the second is that older patients die most
commonly from infectious causes, and the third is that nonstandard
lungs can be used safely for older patients. About the first point, with
which I would tend to agree, that the right selection of recipients al-
lows you to have a successful transplantation, I am curious because
in fact this is a comparison of single-lung transplantations in older
patients versus double-lung transplantations in younger patients,
and therefore we get into how you decide someone received a sin-
gle-lung transplant versus a double-lung transplant for the same dis-
ease because your groups were matched based on their initial
diagnosis. Therefore my question is as follows: in terms of selecting
the older patient for a transplantation procedure, which by default in
your case would be a single-lung transplantation procedure, are
there other things, other specifics, such as right ventricular end-dia-
stolic pressure, ejection fraction, or body mass index, that allow you
to more accurately identify the older patient that you would see as
a potential candidate for transplantation?
Dr Bastani. With regard to your question about more precisely
defining our patient population of 65 years and older, we did not
have enough older patients in the double-lung transplant group to
be able to make an adequate comparison. We did, however, have
a list of relative contraindications for the patients 65 years and older,
some of which were body mass index of less than 18 and greater
than 30, debilitation, and acute renal failure defined by creatinine
clearance. In general, our lung transplantation committee made an
effort not to list patients who had 2 or more of these relative contra-
indications.
Dr Wain. Were those the only relative contraindications? Was
there anything else, such as osteoporosis or bad social history or
any of those other things, that were in the mix?
Dr Bastani. By listing debilitation as one of the relative contra-
indications, we have the ability to introduce some subjectivity, and
yes, osteoarthritis and other characteristics could preclude patients
from receiving a lung transplant.
Dr Wain. The other question I have is this: How do you decide
that a 63-year-old patient with IPF, for example, received a double-
lung transplant and a 65-year-old patient with IPF receives a single-
lung transplant? Is there anything else other than their absolute age
that goes into your decision-making process that lets you decide that
the patient should receive a single- or a double-lung transplant in the
same relative age range?
Dr Bastani. At this time, despite our focus on a population of
patients 65 years and older, there is no absolute contraindication
on upper age limit with respect to single- versus double-lung trans-
plantation. If our lung transplantation committee deems a patient to
be clinically fit, despite advanced age of 65 years and older, he or she
might be a potential candidate for lung transplantation, including
double-lung transplantation.
Dr Wain. With regard to the second point about older patients
dying more of infection, I guess in looking at it I would say that
your data really say that your older patients just die more in that firstThe Journal of Thoyear. I say that because it looked like 6 of 8, or 75%, of the older
group of patients died of infectious causes in the first year, and al-
though the number of younger patients dying was much smaller, 2
of 3 died of those infectious causes. Therefore the first question is
as follows: Was there any specific type of infectious cause that the
patients in either group died of, and then, as an aside to that, was
there a difference between the infectious causes in the 2 groups?
Dr Bastani. Five of the 6 patients in the older group died of in-
fection of bacterial cause, and the other patient died of infection of
fungal cause. There were no patients in this group who died of infec-
tious cause secondary to a viral source. In the younger group both of
the patients died of infection of bacterial cause.
DrWain. Therefore you had bacterial infections in both groups.
Dr Bastani. Yes.
DrWain. Then along those lines, akin to the single- versus dou-
ble-lung transplantation, you have 2 different immunosuppressive
protocols. Was there any suggestion or thought that the difference
in induction immunosuppression might somehow relate to the likeli-
hood of infection or death in the first year? Do you have any other
experience to draw on using the interleukin 2 receptor blocker that
would suggest that is not as good, for instance, as the rabbit ATG
or vice versa?
Dr Bastani. We did not specifically look at that and compare
those 2 groups, although we did initially have a bias for selecting in-
terleukin 2 receptor antibody induction therapy for older patients
and vice versa for the younger patients, but we did not specifically
look at that.
Dr Wain. And why did you come to that bias, or what was the
rationale behind that?
Dr Bastani. Because older patients are more susceptible to im-
munosenescence, our group selects for interleukin 2 receptor anti-
body induction therapy for the older group because of its more
specific and less broadly immunosuppressive action.
DrWain.That is perfectly fine. To the last point in the study, that
nonstandard lungs are okay or safe in older patients, I guess I would
say that might be a little bit overstated. I say that because, having
looked at that table of your donor characteristics, although there
was clearly a preponderance of lungs from older donors in your
older age group, functionally the lungs seemed much the same in
terms of their overall PO2, and in fact, there was a little trend for a pre-
ponderance of donors who had a significant smoking history in the
younger group compared with the older group. Recognizing that
elastic fibers deteriorate as you get older and that sort of thing, if I
needed a lung transplantation, I personally would want a lung
from a 60-year-old marathon runner instead of a 48-year-old indi-
vidual who smoked a lot. I just wondered if there are any other pa-
rameters, smoking, for instance, that you look at more critically
than, say, age, which is a crude marker at best, in terms of trying
to select donor lungs for older patients or patients who you might
consider at higher risk.
Dr Bastani.We were surprised by our findings that a larger pro-
portion of the patients in the younger group received lungs from
smokers. We did look at other parameters. One of the parameters
was donor age greater than 55 years. There were also other param-
eters that we examined. Other studies demonstrate smoking history
to be a significant predictor as well. I am not certain whether this
finding will be predictive of a negative outcome in our younger pa-
tients, but we did examine other nonstandard donor lung parameters.racic and Cardiovascular Surgery c Volume 135, Number 2 419
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had multiple criteria that met the nonstandard donor lung parameters
compared with the younger patients, who had a single-criterion pa-
rameter.
Dr Wain. I have 1 final question about selecting donor lungs. Is
there anything that you can think of or anything that you routinely
do that is a little more precise than just donor age or smoking history
or, you know, what the chest radiograph looks like? Do you do any
routine chest computed tomographic scanning or routine bronchoal-
veolar lavage or something like that that would give us a better sense
of the kind of true anatomic and inflammatory state of the donor lung
than just what the PO2 is at some little snapshot in time or the donor’s
age?
Dr Bastani. At our institution, we routinely perform bronchos-
copies on all donor lungs, and if, for example, there is any question
of whether there is an infiltrate on chest radiography or there are any
significant findings on bronchoscopy, we do perform chest com-
puted tomographic scanning on those patients; however, we do
not routinely perform chest computed tomographic scanning on
all donors.
Dr Wain. Again, congratulations, and thanks very much for
letting me see the manuscript ahead of time.
Dr Yoshiya Toyoda (Pittsburgh, Pa). Congratulations on your
excellent presentation and outcome.
I would like to make a comment. Over the last year and a few
months, I have done 66 lung transplantations, and of these, 18 pa-
tients, about 25%, were age 65 years and older, including an 81-
year-old man for whom I did a left single-lung transplantation for
his IPF and moderate pulmonary hypertension. Fortunately, 30-
day survival has been 100%, but I lost 2 patients, one from Pseudo-
monas-induced pneumonia and the other from sepsis. Therefore I
agree with your conclusion. Probably these older patients should
be managed with less immunosuppression.
Dr Bastani. Thank you.
Dr Walter Klepetko (Vienna, Austria). I enjoyed your article
very much, and I want to congratulate you on these very good out-
come data.
One thing was surprising to me and struck me a bit. You showed
us an approximate freedom from BOS of only 50% after 1 or 11ˇ/2
years. This is somewhat low compared with data that we recently
have heard in which several multicenter studies have shown free-
dom from BOS after 3 years in the range of 75% to 80%. Do you
think that at least in the cohort of your older patients that this is
the price you are paying now when you are using lungs that are420 The Journal of Thoracic and Cardiovascular Surgery c Febnot so ideal on the one hand and on the other hand potentially
have altered your immunosuppressive regimen in a way that BOS
might likely occur more frequently?
Dr Bastani.We were surprised by the pattern in which patients
demonstrated the incidence of BOS, particularly the older patients,
in whom there was a steady decrease in the incidence of BOS-free
survival, and then that leveled off. BOS was one of the secondary
end points that we examined. One explanation for differences in
our data compared with those of the multicenter study you just
eluded to might be in our definition of BOS; we defined BOS as
a 20% or greater decrease in forced expiratory volume in 1 second.
We did not routinely treat all patients with BOS or perform biopsies
on all patients with BOS.
DrKlepetko. I have one question regarding your acceptance cri-
teria. You had obstructive cardiovascular disease as an exclusion
criteria. How did you handle patients in whom the obstructive dis-
ease was already fixed, let us say, having a history of a bypass
operation 2 years before or a stent application with no further
obstructions there at the time of their evaluation?
Dr Bastani. Patients with prior history of percutaneous translu-
minal coronary angioplasty or bypass operation to correct obstruc-
tive coronary artery disease who were deemed to be free of
coronary artery disease, as assessed by means of left heart catheter-
ization, at the time of presentation to the lung transplantation com-
mittee were not excluded from consideration for lung
transplantation.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). I really en-
joyed your presentation.
We actually have an article that was just published this week (Am
J Transplant. 2007;7:1271-7) in which we compared outcomes of
lung transplantation in older and younger patients, and even with
age-adjusted mortality, we did find a higher risk of death over
time after lung transplantation in patients older than 60 years versus
those younger than 50 years. When you compare at a specific age
cutoff, such as older than 65 versus less than 65 years, there is not
much of a difference between a 64-year-old and a 66-year-old.
Did you look at your data with a wider age spread to see whether
you have an age difference?
Dr Bastani. We did not examine our subset of populations,
for example, 60 to 64 years, to determine whether survival was
similar to that seen in those older than 65 years or maybe those youn-
ger than 60 years, but certainly that is something that I think we need
to go back and look at to see whether we need to redefine our
parameters.ruary 2008
